Skip to main content

Table 2 Characteristics of patients initiating HCV treatment with 2nd-wave DAA-based regimens in 2014–2015, France

From: Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

  2014 2015
  Men Women Total Men Women Total
  % % n % % % n %
Total 65.9 34.1 8702 100 64.4 35.6 14,650 100
Age group (years)a
  < 30 0.3 0.3 30 0.3 0.8 0.7 112 0.8
 30–39 2.6 1.3 184 2.1 4.3 2.1 519 3.5
 40–49 20.6 9.4 1461 16.8 20.5 9.6 2441 16.7
 50–59 50.1 30.5 3776 43.4 48.2 31.8 6204 42.4
 60–69 18.6 31.0 1985 22.8 17.6 27.1 3068 20.9
 70–79 6.3 22.1 1015 11.7 6.5 21.2 1716 11.7
 80 and over 1.5 5.4 249 2.9 2.1 7.5 585 4.0
Complementary Universal Health insurance (CMUC)a
 Yes 15.5 11.3 1218 14.0 17.3 12.6 2291 15.6
State Medical Assistance (AME)a
 Yes 0.9 1.4 93 1.1 2.1 1.9 298 2.0
Long-term disease status (LTD) for HCVb
 Yes 53.4 56.9 4276 54.6 43.2 48.9 6017 45.3
Previous HCV treatment initiation between 2007 and 2013
 No 52.5 59.8 4786 55.0 72.1 74.9 10,703 73.1
 Yesc 47.5 40.2 3916 45.0 27.9 25.1 3947 26.9
   with PEG-IFN/RBV bitherapy only 72.5 72.1 2833 72.4 81.3 80.6 3200 81.1
   with 1st-wave PIs only 12.6 13.6 506 12.9 9.3 10.9 388 9.8
   with PEG-IFN/RBV bitherapy and 1st-wave PIs 14.9 14.3 575 14.7 9.4 8.5 359 9.1
  1. PEG-IFN Pegylated Interferon α, RBV Ribavirin, 1st- wave PIs first-wave protease inhibitors
  2. aMissing values: in 2014, 2 patients for age, 13 patients for CMUC and AME; in 2015, 5 patients for age
  3. bThis data was available only for beneficiaries of the general insurance scheme
  4. cPrevious HCV treatment initiation with 2nd- wave DAAs in 2013 for 2 patients